Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and non...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakkassery, Helen, Carpenter, Esme, Patten, Piers E.M., Irshad, Sheeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345889/
https://www.ncbi.nlm.nih.gov/pubmed/35999131
http://dx.doi.org/10.1016/j.molmed.2022.07.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345889/
https://www.ncbi.nlm.nih.gov/pubmed/35999131
http://dx.doi.org/10.1016/j.molmed.2022.07.006

Ejemplares similares